Compare First Citizens BancShares Inc (FCNCA) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs Novavax Inc — how do they compare? First Citizens BancShares Inc trades at $2,173.73 (market cap $23.76B), while Novavax Inc trades at $8.21 (market cap $1.39B). The key difference: First Citizens BancShares Inc is far larger — about 17.1× Novavax Inc's market cap, and First Citizens BancShares Inc pays a 0.41% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| FCNCA | NVAX | |
|---|---|---|
Market Cap | $23.76B | $1.39B |
Sector | Sector/Thematic | Health |
52-Week High | $2.20K | $11.19 |
52-Week Low | $1.64K | $6.22 |
Dividend Yield | 0.41% | — |
Enterprise Value | — | $890.94M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $8.21, down 2.49% amid bearish technical signals and negative cash flow trends. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 and three consecutive earnings beats, but faces profitability challenges with negative net income margin and ROE. Recent news highlights shareholder dissent and underperformance versus broader market trends, while analyst consensus remains bullish with a $14 price target representing 70% upside potential.
The outlook balances significant upside potential against substantial execution risks. Positive catalysts include consistent earnings beats and strong analyst support, but concerns persist around cash burn, negative equity, and competitive vaccine market pressures. Investors face volatility from operational challenges despite attractive valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
